Haemonetics Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4050241003
USD
83.81
1.9 (2.32%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Haemonetics Corp. stock-summary
stock-summary
Haemonetics Corp.
Pharmaceuticals & Biotechnology
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.
Company Coordinates stock-summary
Company Details
125 SUMMER STREET , BOSTON MA : 02110
stock-summary
Tel: 1 781 84871001 781 3569763
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 113 Schemes (52.28%)

Foreign Institutions

Held by 153 Foreign Institutions (14.09%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Richard Meelia
Independent Chairman of the Board
Mr. Christopher Simon
President, Chief Executive Officer, Director
Mr. Robert Abernathy
Independent Director
Ms. Catherine Burzik
Independent Director
Mr. Michael Coyle
Independent Director
Mr. Charles Dockendorff
Independent Director
Dr. Mark Kroll
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
321 Million
(Quarterly Results - Jun 2025)
Net Profit:
34 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,606 Million (Small Cap)

stock-summary
P/E

22.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.06

stock-summary
Return on Equity

18.06%

stock-summary
Price to Book

2.95